The use of the dopamine-receptor partial agonist aripiprazole in the treatment of restless legs syndrome [2]

Sleep

Volumn 27, Issue 5, 2004, Pages 1022-

  McLean, Andrew J ^a  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CLOMIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PARTIAL AGONIST; QUETIAPINE;

ADULT; AKATHISIA; ANXIETY DISORDER; CASE REPORT; DRUG EFFICACY; HUMAN; INSOMNIA; LETTER; MALE; PARANOIA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME;

ADULT; DOPAMINE AGONISTS; HUMANS; MALE; PIPERAZINES; QUINOLONES; RESTLESS LEGS SYNDROME;

EID: 4143139800     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Becker PM, Jamieson AO, Brown WD. Insomnia. Postgrad Med 1993;93:66-70.
2. Krueger BR. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc 1990;65:999-1006.
3. McCall WV, Rakel RE. A Practical Guide to Insomnia. New York: McGraw-Hill; 1999.
4. Lieberman J. Potential scientific and clinical significance with the introduction of aripiprazole. Presented at Vision Aripiprazole Worldwide Schizophrenia Summit II. Bal Harbour, FL, April 9, 2002.
5. rd ed. Philadelphia: Williams & Wilkins; 1998.